Have a personal or library account? Click to login
Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data) Cover

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)

Acta Medica Bulgarica
Volume 47 (2020): Issue 4 (November 2020)
By: V. Varbanova,  A. Anastasova-Postadzhiyan,  A. Nedeva,  I. Nikolov,  I. Kindekov,  Y. Kuyumdzhieva,  N. Petkova,  E. Vikentieva,  M. Lubomir and  J. Raynov  
Open Access
|Nov 2020
DOI: https://doi.org/10.2478/amb-2020-0043 | Journal eISSN: 2719-5384 | Journal ISSN: 0324-1750
Journal RSS Feed
Language: English
Page range: 38 - 43
Accepted on: Dec 20, 2019
Published on: Nov 24, 2020
Published by: Sofia Medical University
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
azacytidine,
MDS,
AML,
CMML-2
Related subjects:
Medicine,
Basic medical science,
Immunology,
Clinical medicine,
Clinical medicine, other

© 2020 V. Varbanova, A. Anastasova-Postadzhiyan, A. Nedeva, I. Nikolov, I. Kindekov, Y. Kuyumdzhieva, N. Petkova, E. Vikentieva, M. Lubomir, J. Raynov, published by Sofia Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 47 (2020): Issue 4 (November 2020)Next article